Abstract
MDS patients, with an overall erythroid response of 22.6%. The mechanism leading to haematological improvement, which seems to be dependent on serum ferritin reductions, remains to be elucidated. Factors that may play a role in this improvement include: reduction in iron overload with concomitant reduction in oxidative stress, specific pharmacological effect of the drug on haematopoiesis such as the ability to inhibit nuclear factor uB, or both. These analyses support previous observations reporting the ability of deferasirox to improve haematologic parameters in transfusion-dependent patients with MDS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
